PHILADELPHIA — Seasonal epidemics of influenza result in nearly 36,000 deaths annually in the United States, according to the Centers for Disease Control. Current vaccines against the influenza virus elicit an antibody response specific for proteins on the outside of the virus, specifically the hemagglutinin (HA) protein.
Yearly vaccines are made by growing the flu virus in eggs. The viral envelope proteins, including HA, are cleaved off and used as the vaccine, but vary from year to year, depending on what flu strains are prevalent. However, high mutation rates in envelope HA proteins result in the emergence of new viral types each year, which elude neutralization by preexisting antibodies in the body (specifically the HA proteins’ specific receptor binding sites that are the targets of neutralizing antibodies). On the other hand, other immune cell types are capable of mediating protection through recognition of other, more conserved parts of HAs or highly conserved internal proteins in the influenza virus.
E. John Wherry, PhD, associate professor of Microbiology and director of the Institute for Immunology at the Perelman School of Medicine, University of Pennsylvania, and colleagues, report in PLOS Pathogens that influenza virus-specific CD8+ T cells or virus-specific non-neutralizing antibodies are each relatively ineffective at conferring protective immunity alone. But, when combined, the virus-specific CD8 T cells and non-neutralizing antibodies cooperatively elicit robust protective immunity.
This synergistic improvement in protective immunity is dependent, at least in part, on other immune cells -- lung macrophages and phagocytes. An implication of this work is that immune responses targeting parts of the virus that are not highly variable can be combined for effective protection.
“The two-pronged approach is synergistic, so by enlisting two suboptimal vaccine approaches, we achieved a better effect than each alone in an experimental model,” says Wherry. “Now, we are rethinking past approaches and looking for ways to combine T-cell vaccines and antibody vaccines to make a more effective combined vaccine.”
“Overall, our studies suggest that an influenza vaccine capable of eliciting both CD8+ T cells and antibodies specific for highly conserved influenza proteins may be able to provide protection in humans, and act as the basis for a potential ‘universal’ vaccine,” says Wherry.
These results suggest a novel strategy that could potentially form a primary component of a universal influenza vaccine capable of providing long-lasting protection.
Co-authors include Brian J. Laidlaw, Vilma Decman, Mohammed-Alkhatim A. Ali, Michael C. Abt, Amaya I. Wolf, Laurel A. Monticelli, Krystyna Mozdzanowska, Jill M. Angelosanto, David Artis, and Jan Erikson.
The research was supported by grants from the National Institute for Allergy and Infectious Diseases (HHSN272201100018C, AI077098).
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.